Description

Retatrutide 20mg + Tirzepatide 40mg is a multi-agonist research peptide formulation designed for advanced laboratory investigation of incretin and metabolic receptor signaling pathways. This dual-compound blend combines Retatrutide, a triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, with Tirzepatide, a dual GLP-1/GIP receptor agonist.

In controlled research environments, this formulation is utilized to explore complex multi-receptor pathway interactions, endocrine signaling coordination, and metabolic regulation frameworks. The combination allows researchers to evaluate overlapping and complementary incretin receptor activation mechanisms within experimental systems.

In preclinical and in vitro research models, this blend is commonly studied for:

GLP-1 receptor pathway analysis

GIP receptor signaling investigations

Glucagon receptor modulation studies

Multi-receptor metabolic modeling

Energy balance and endocrine feedback research

Sustained receptor activation dynamics

Due to the presence of both dual- and triple-agonist components, this formulation is positioned for advanced metabolic research applications requiring multi-pathway evaluation under controlled laboratory conditions.

Supplied in lyophilized form to ensure stability, handling precision, and reproducibility in research settings.

Strictly intended for laboratory research use only. Not for human or veterinary use.